Back to Journals » Patient Preference and Adherence » Volume 11

Using a multidimensional unfolding approach to assess multiple sclerosis patient preferences for disease-modifying therapy: a pilot study

Authors Sempere AP, Vera-Lopez V, Gimenez-Martinez J, Ruiz-Beato E, Cuervo J, Maurino J

Received 3 December 2016

Accepted for publication 14 March 2017

Published 29 May 2017 Volume 2017:11 Pages 995—999

DOI https://doi.org/10.2147/PPA.S129356

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Doris Leung

Peer reviewer comments 3

Editor who approved publication: Dr Johnny Chen

Angel Perez Sempere,1 Vanesa Vera-Lopez,2 Juana Gimenez-Martinez,1 Elena Ruiz-Beato,3 Jesús Cuervo,4 Jorge Maurino5

1Department of Neurology, Hospital General Universitario de Alicante, Alicante, 2Department of Statistics, University of Salamanca, Salamanca, 3Health Economics and Outcomes Research Unit, Roche Farma SA, Madrid, 4Health Economics and Outcomes Research, Oviedo, 5Medical Department, Roche Farma SA, Madrid, Spain

Purpose: Multidimensional unfolding is a multivariate method to assess preferences using a small sample size, a geometric model locating individuals and alternatives as points in a joint space. The objective was to evaluate relapsing–remitting multiple sclerosis (RRMS) patient preferences toward key disease-modifying therapy (DMT) attributes using multidimensional unfolding.
Patients and methods: A cross-sectional pilot study in RRMS patients was conducted. Drug attributes included relapse prevention, disease progression prevention, side-effect risk and route and schedule of administration. Assessment of preferences was performed through a five-card game. Patients were asked to value attributes from 1 (most preferred) to 5 (least preferred).
Results: A total of 37 patients were included; the mean age was 38.6 years, and 78.4% were female. Disease progression prevention was the most important factor (51.4%), followed by relapse prevention (40.5%). The frequency of administration had the lowest preference rating for 56.8% of patients. Finally, 19.6% valued the side-effect risk attribute as having low/very low importance.
Conclusion: Patients’ perspective for DMT attributes may provide valuable information to facilitate shared decision-making. Efficacy attributes were the most important drug characteristics for RRMS patients. Multidimensional unfolding seems to be a feasible approach to assess preferences in multiple sclerosis patients. Further elicitation studies using multidimensional unfolding with other stated choice methods are necessary to confirm these findings.

Keywords:
multiple sclerosis, multidimensional unfolding, patient preferences, disease-modifying therapy, decision-making
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Herding: a new phenomenon affecting medical decision-making in multiple sclerosis care? Lessons learned from DIScUTIR MS

Saposnik G, Maurino J, Sempere AP, Ruff CC, Tobler PN

Patient Preference and Adherence 2017, 11:175-180

Published Date: 31 January 2017

Prevalence of metabolic syndrome according to the presence of negative symptoms in patients with schizophrenia

Sicras-Mainar A, Maurino J, Ruiz-Beato E, Navarro-Artieda R

Neuropsychiatric Disease and Treatment 2015, 11:51-57

Published Date: 30 December 2014